Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Similar articles for PubMed (Select 24096239)

1.

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.

Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY.

J Infect. 2013 Dec;67(6):606-16. doi: 10.1016/j.jinf.2013.09.029. Epub 2013 Oct 3.

PMID:
24096239
2.

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays.

Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG Jr, Frieman MB, Holbrook MR, Jahrling PB, Hensley L.

J Gen Virol. 2014 Mar;95(Pt 3):571-7. doi: 10.1099/vir.0.061911-0. Epub 2013 Dec 9.

3.

Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.

Hui DS, Memish ZA, Zumla A.

Curr Opin Pulm Med. 2014 May;20(3):233-41. doi: 10.1097/MCP.0000000000000046. Review.

PMID:
24626235
4.

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.

de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, Posthuma CC, van der Meer Y, Bárcena M, Haagmans BL, Snijder EJ, van den Hoogen BG.

J Gen Virol. 2013 Aug;94(Pt 8):1749-60. doi: 10.1099/vir.0.052910-0. Epub 2013 Apr 25.

5.

Indomethacin has a potent antiviral activity against SARS coronavirus.

Amici C, Di Coro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG.

Antivir Ther. 2006;11(8):1021-30.

PMID:
17302372
6.

Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.

Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA.

Int J Infect Dis. 2013 Oct;17(10):e792-8. doi: 10.1016/j.ijid.2013.07.002. Epub 2013 Aug 29. Review.

7.

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.

Al-Tawfiq JA, Momattin H, Dib J, Memish ZA.

Int J Infect Dis. 2014 Mar;20:42-6. doi: 10.1016/j.ijid.2013.12.003. Epub 2014 Jan 6.

8.

Family cluster of Middle East respiratory syndrome coronavirus infections.

Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM.

N Engl J Med. 2013 Jun 27;368(26):2487-94. doi: 10.1056/NEJMoa1303729. Epub 2013 May 29. Erratum in: N Engl J Med. 2013 Aug 8;369(6):587.

9.

Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations.

Abdel-Moneim AS.

Arch Virol. 2014 Jul;159(7):1575-84. doi: 10.1007/s00705-014-1995-5. Epub 2014 Feb 11. Review.

PMID:
24515532
10.

Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.

Strayer DR, Dickey R, Carter WA.

Infect Disord Drug Targets. 2014;14(1):37-43. Review.

PMID:
25019238
11.

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.

Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H.

Nat Med. 2013 Oct;19(10):1313-7. doi: 10.1038/nm.3362. Epub 2013 Sep 8.

12.

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread.

Lu L, Liu Q, Du L, Jiang S.

Microbes Infect. 2013 Jul-Aug;15(8-9):625-9. doi: 10.1016/j.micinf.2013.06.003. Epub 2013 Jun 19. Review.

PMID:
23791956
13.

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26. doi: 10.1073/pnas.1402074111. Epub 2014 Apr 28.

14.

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM.

Lancet Infect Dis. 2014 Nov;14(11):1090-5. doi: 10.1016/S1473-3099(14)70920-X. Epub 2014 Sep 29. Erratum in: Lancet Infect Dis. 2015 Jan 15;211(2):13.

PMID:
25278221
15.

Coronaviruses and their therapy.

Haagmans BL, Osterhaus AD.

Antiviral Res. 2006 Sep;71(2-3):397-403. Epub 2006 Jun 19. Review.

PMID:
16837072
16.

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.

Shirato K, Kawase M, Matsuyama S.

J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13. Epub 2013 Sep 11.

17.

[Etiological, epidemiological and clinical aspects of coronavirus infection MERS-CoV].

Gańczak M.

Pol Merkur Lekarski. 2015 Jan;38(223):46-50. Review. Polish.

PMID:
25763589
18.

Molecular pathology of emerging coronavirus infections.

Gralinski LE, Baric RS.

J Pathol. 2015 Jan;235(2):185-95. doi: 10.1002/path.4454. Review.

19.

Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.

Kilianski A, Baker SC.

Antiviral Res. 2014 Jan;101:105-12. doi: 10.1016/j.antiviral.2013.11.004. Epub 2013 Nov 20. Review.

20.

A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case.

Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM.

Int J Infect Dis. 2013 Sep;17(9):e668-72. doi: 10.1016/j.ijid.2013.07.001. Epub 2013 Aug 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk